200 related articles for article (PubMed ID: 38524631)
1. Anti-osteoporotic treatments in the era of non-alcoholic fatty liver disease: friend or foe.
Chondrogianni ME; Kyrou I; Androutsakos T; Flessa CM; Menenakos E; Chatha KK; Aranan Y; Papavassiliou AG; Kassi E; Randeva HS
Front Endocrinol (Lausanne); 2024; 15():1344376. PubMed ID: 38524631
[TBL] [Abstract][Full Text] [Related]
2. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
3. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
[TBL] [Abstract][Full Text] [Related]
4. Non-alcoholic fatty liver disease.
Powell EE; Wong VW; Rinella M
Lancet; 2021 Jun; 397(10290):2212-2224. PubMed ID: 33894145
[TBL] [Abstract][Full Text] [Related]
5. The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease.
Chrysavgis L; Papatheodoridi AM; Chatzigeorgiou A; Cholongitas E
J Gastroenterol Hepatol; 2021 Apr; 36(4):893-909. PubMed ID: 33439540
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: A Bidirectional Relationship.
Muzica CM; Sfarti C; Trifan A; Zenovia S; Cuciureanu T; Nastasa R; Huiban L; Cojocariu C; Singeap AM; Girleanu I; Chiriac S; Stanciu C
Can J Gastroenterol Hepatol; 2020; 2020():6638306. PubMed ID: 33425804
[TBL] [Abstract][Full Text] [Related]
7. [Non-alcoholic fatty liver disease; a full-bodied epidemic].
Tushuizen ME; Holleboom AG; Koot BGP; Blokzijl H; van Mil SWC; Koek GH
Ned Tijdschr Geneeskd; 2020 Feb; 164():. PubMed ID: 32267638
[TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
Streba LA; Vere CC; Rogoveanu I; Streba CT
World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
[TBL] [Abstract][Full Text] [Related]
9. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
Estes C; Anstee QM; Arias-Loste MT; Bantel H; Bellentani S; Caballeria J; Colombo M; Craxi A; Crespo J; Day CP; Eguchi Y; Geier A; Kondili LA; Kroy DC; Lazarus JV; Loomba R; Manns MP; Marchesini G; Nakajima A; Negro F; Petta S; Ratziu V; Romero-Gomez M; Sanyal A; Schattenberg JM; Tacke F; Tanaka J; Trautwein C; Wei L; Zeuzem S; Razavi H
J Hepatol; 2018 Oct; 69(4):896-904. PubMed ID: 29886156
[TBL] [Abstract][Full Text] [Related]
10. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
11. The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review.
Zachou M; Flevari P; Nasiri-Ansari N; Varytimiadis C; Kalaitzakis E; Kassi E; Androutsakos T
Eur J Clin Pharmacol; 2024 Jan; 80(1):127-150. PubMed ID: 37938366
[TBL] [Abstract][Full Text] [Related]
12. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
[TBL] [Abstract][Full Text] [Related]
13. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis.
Quek J; Chan KE; Wong ZY; Tan C; Tan B; Lim WH; Tan DJH; Tang ASP; Tay P; Xiao J; Yong JN; Zeng RW; Chew NWS; Nah B; Kulkarni A; Siddiqui MS; Dan YY; Wong VW; Sanyal AJ; Noureddin M; Muthiah M; Ng CH
Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):20-30. PubMed ID: 36400097
[TBL] [Abstract][Full Text] [Related]
14. New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis.
Pydyn N; Miękus K; Jura J; Kotlinowski J
Pharmacol Rep; 2020 Feb; 72(1):1-12. PubMed ID: 32016853
[TBL] [Abstract][Full Text] [Related]
15. What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
Doumas M; Imprialos K; Stavropoulos K; Athyros VG
Curr Vasc Pharmacol; 2019; 17(5):425-428. PubMed ID: 31418344
[TBL] [Abstract][Full Text] [Related]
16. Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver Cancer.
Wang K; Wei Y; Xu R; Li Y; Mao C
Adv Exp Med Biol; 2022; 1372():157-168. PubMed ID: 35503180
[TBL] [Abstract][Full Text] [Related]
17. Relationship between prevalence and risk of osteoporosis or osteoporotic fracture with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Pan B; Cai J; Zhao P; Liu J; Fu S; Jing G; Niu Q; Li Q
Osteoporos Int; 2022 Nov; 33(11):2275-2286. PubMed ID: 35764892
[TBL] [Abstract][Full Text] [Related]
18. Non-alcoholic fatty liver disease: A growing public health problem in Turkey.
Kaya E; Yılmaz Y
Turk J Gastroenterol; 2019 Oct; 30(10):865-871. PubMed ID: 31258135
[TBL] [Abstract][Full Text] [Related]
19. Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight.
Ballestri S; Nascimbeni F; Romagnoli D; Baldelli E; Targher G; Lonardo A
Int J Mol Sci; 2016 Mar; 17(3):355. PubMed ID: 27005620
[TBL] [Abstract][Full Text] [Related]
20. Treatment responses and outcomes in patients with autoimmune hepatitis and concomitant features of non-alcoholic fatty liver disease.
Zachou K; Azariadis K; Lytvyak E; Snijders RJALM; Takahashi A; Gatselis NK; Robles M; Andrade RJ; Schramm C; Lohse AW; Tanaka A; Drenth JPH; Montano-Loza AJ; Dalekos GN;
JHEP Rep; 2023 Aug; 5(8):100778. PubMed ID: 37456672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
